An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2024.2428311
Abstract: ABSTRACT Introduction Risankizumab (RZB) is a recombinant IgG1 humanized monoclonal antibody which selectively inhibits interleukin (IL)-23 though high-affinity binding of the p19 subunit. RZB was approved for use in Crohn’s disease (CD) in 2022 and… read more here.
Keywords: rzb; evaluation risankizumab; treatment; ulcerative colitis ... See more keywords